



## **ObsEva SA to Participate in BMO Healthcare Conference December 14<sup>th</sup> 2017**

**Geneva, Switzerland and Boston, MA –December 7, 2017** – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that company management will participate in the BMO Prescriptions for Success Healthcare Conference on December 14<sup>th</sup>, 2017, in New York City.

ObsEva’s presentation will take place on Thursday, December 14<sup>th</sup>, 2017, at 3.00 p.m. Eastern Time (ET). A webcast will be available in the “Investors” section of ObsEva’s website [www.ObsEva.com](http://www.ObsEva.com).

### **About ObsEva**

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit [www.ObsEva.com](http://www.ObsEva.com).

###

### **Media Contact:**

Liz Bryan  
Spectrum Science  
[lbryan@spectrumscience.com](mailto:lbryan@spectrumscience.com)  
+1 202-955-6222 x2526

### **Company Contact:**

CEO Office contact  
Shauna Dillon  
[Shauna.dillon@obseva.ch](mailto:Shauna.dillon@obseva.ch)  
+41 22 552 1550

### **Investor Contact**

Mario Corso  
Senior Director, Investor Relations  
[mario.corso@obseva.com](mailto:mario.corso@obseva.com)  
+1 781-366-5726